Robert F. Kennedy Jr.'s Health Department has sent a plan to ease limits on popular peptide drugs to the White House, a step allies hail as medical freedom.
Health Secretary Robert F. Kennedy Jr.'s department submitted a peptides “interim access policy” to the White House this week, Breitbart reported. The plan went to the Office of Management and Budget, which reviews federal rules with major economic impact.
Two people familiar with the proposal said it is meant to let compounding pharmacies temporarily produce some of the most popular peptides, including BPC-157. The approach would use enforcement discretion so those pharmacies are not targeted for making certain products the Food and Drug Administration has restricted.
HHS officials did not immediately respond to requests for comment on the day the filing appeared on a government website. The White House filing itself does not spell out the full details of the new policy.
Before joining the administration, Kennedy publicly said the “FDA’s war” on peptides and other wellness products would soon end. After taking office as health secretary, he argued that U.S. compounding pharmacies must be allowed to sell peptides.
His stated reason was straightforward. Americans were increasingly turning to “gray market” peptides made in China and other countries. Those products remain widely available for purchase on platforms such as TikTok, even as domestic compounding stays under tight limits.
Kennedy earlier this year directed the FDA to reconsider a short list of chemicals widely promoted by wellness influencers and fitness celebrities. The new interim policy fits that same push to open lawful domestic channels rather than leave demand to overseas sellers.
That focus on agency accountability tracks other fights Kennedy has picked at HHS, including when Kennedy accused Biden-era HHS of weakening fraud oversight and leaving billions exposed.
In July, a panel of external FDA advisers recommended the agency drop its restrictions on six of the seven peptides put before them. That advice ran against the conclusion of FDA staff scientists, who said none of the peptides had been studied enough to establish safety and effectiveness.
The FDA had previously placed BPC-157 and more than a dozen other injectable peptides on its list of substances too risky to be compounded by pharmacies. Possible risks cited by the agency include contamination, allergic reactions, and tumor growth.
Most of the available data on these peptides comes from animal studies. Uses promoted in the wellness world include bulking up, looking younger, or boosting energy. None of those uses are approved by the FDA.
Formal addition of the substances to the FDA’s list of drugs treated as safe for compounding would require full federal rulemaking. That process can take years and multiple rounds of public comment. It is not immediately clear whether the administration still plans to pursue that longer track alongside the interim step.
Kennedy’s broader challenge to entrenched public-health orthodoxy has been a steady theme, from peptide policy to earlier clashes in which RFK Jr. said newly disclosed messages showed Anthony Fauci misled the public on COVID.
Major telehealth providers Hims & Hers and Noom recently announced plans to offer peptides to customers if the federal government eases access. Wall Street analysts estimate the market could be worth $2 billion to $3 billion.
Brigham Buhler, a wellness clinic operator who sells peptides through an online service and is described as a Kennedy ally, quickly praised the proposal on X.
Buhler posted:
“This is huge.”
He added:
“This isn’t about whether you’re for or against peptides. It’s about whether you’re for or against MEDICAL FREEDOM.”
Compounding pharmacies are specialty businesses that mix customized medications not available from traditional drugmakers. An interim policy built on enforcement discretion would give them temporary room to operate without waiting for multi-year rulemaking.
Public-health power and personal choice have collided for years in Washington. Critics of the old COVID-era approach still point to cases like the moment a White House vaccine adviser said Fauci violated his oath through shutdowns and the vaccine push.
Kennedy’s case rests on a basic trade-off. Keep strict compounding bans in place, and more Americans keep buying peptides from overseas gray markets. Open temporary domestic compounding under clear enforcement limits, and patients and clinics gain a regulated U.S. channel while longer scientific review continues.
The FDA’s risk list and staff scientists’ caution remain on the record. Contamination, allergic reactions, and tumor growth are the hazards the agency has flagged. External advisers, selected by HHS, reached a different judgment on six of seven peptides reviewed in July.
Unproven products have been popular inside the Make America Healthy Again movement. Some of the biggest figures in that world sell peptide injections and supplements. The interim policy would move a slice of that demand from informal online sales toward compounding pharmacies operating under federal discretion.
Congressional pressure over pandemic-era decision-making has not faded either, including the hearing where Fauci pleaded the Fifth dozens of times as Sen. Rand Paul pressed for answers.
What the interim filing does not yet answer is the exact roster of peptides beyond BPC-157, how long “temporary” lasts, and whether full rulemaking to add these substances to the safe-for-compounding list will follow. Those details sit with OMB review and any later FDA action.
For now, the Trump administration has moved the policy from HHS into White House clearance. Kennedy said the old restrictions were driving Americans toward foreign gray-market products. The interim plan is the first concrete step to test a different approach at home.
When federal agencies wall off legal U.S. options while overseas sellers fill the gap, patients lose and bureaucrats keep the gate. Opening a supervised compounding path is the common-sense answer the public was owed years ago.
